Life Sciences — Operating Income (Loss)
Danaher Life Sciences — Operating Income (Loss) increased by 51.4% to $336.00M in Q4 2025 compared to the prior quarter. Year-over-year, this metric declined by 10.6%, from $376.00M to $336.00M. Over 2 years (FY 2023 to FY 2025), Life Sciences — Operating Income (Loss) shows a downward trend with a -34.4% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates improved operational efficiency or higher margins; a decrease suggests rising costs or declining pricing power.
Detailed definition
The profit or loss generated by the Life Sciences segment after deducting operating expenses from revenue. This metric e...
Peer comparison
Standard metric for segment performance across all public companies; essential for benchmarking against industry peers.
dhr_segment_life_sciences_operating_income_lossHistorical Data
| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.14B | $975.00M | $1.12B | $1.17B | $1.05B | $321.00M | $340.00M | $313.00M | $235.00M | $235.00M | $233.00M | $35.00M | $376.00M | $201.00M | -$239.00M | $222.00M | $336.00M |
| QoQ Change | — | -14.8% | +14.7% | +5.0% | -11.0% | -69.3% | +5.9% | -7.9% | -24.9% | +0.0% | -0.9% | -85.0% | +974.3% | -46.5% | -218.9% | +192.9% | +51.4% |
| YoY Change | — | — | — | +2.6% | +7.2% | -71.3% | -71.0% | -70.0% | — | -26.8% | -31.5% | -88.8% | +60.0% | -14.5% | -202.6% | +534.3% | -10.6% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Danaher's life sciences — operating income (loss)?
- Danaher (DHR) reported life sciences — operating income (loss) of $336.00M in Q4 2025.
- How has Danaher's life sciences — operating income (loss) changed year-over-year?
- Danaher's life sciences — operating income (loss) decreased by 10.6% year-over-year, from $376.00M to $336.00M.
- What is the long-term trend for Danaher's life sciences — operating income (loss)?
- Over 2 years (2023 to 2025), Danaher's life sciences — operating income (loss) has grown at a -34.4% compound annual growth rate (CAGR), from $1.21B to $520.00M.
- What does life sciences — operating income (loss) mean?
- The profit earned from core business operations before interest and taxes.